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Abstract  
 
Background:The relation  between fibrosis biomarkers, suppressors or activators of fibrosis is 
incompletely studied in CHF of increasing severity.  
Aim of the present study is to investigate serum concentrations of fibrosis inductors, suppressors 
and  regulators in patients with CHF of increasing severity and possible correlations between 
biomarkers and heart functional indexes. 
Methods: ELISA tests were used to quantify TGFβ1, TGFβR1,2, FGFa and b, procollagen 
type(PIP) I, PIP III, Collagen I, III, BMP1,2,3,7, SDF1α, CXCR4, Fibulin 1,2,3, BMPER, CRIM1 
and BAMBI in serum of 66 patients with CHF of increasing severity according to New York Heart 
Association (NYHA class I, n=9; II, n=34; and III n=23), and in 14 healthy subjects matched for 
age and sex.  
Results: TGFβR2, PIP III, SDF1α and CRIM1 were significantly increased in CHF of increasing 
severity (Kruskal Wallis (KW): p=0.0176, p=0.0021, p=0.0017 and p=0.0332, respectively). In 
patients with CHF, PIP III correlated significantly with TGFβR2 (r=+0.29, p=0.026) and CRIM1 
(r=+0.38, p=0.0052). PIP III and CRIM1 correlated significantly with the six minute walking test 
(6’WT) (r=-0.37, p=0.008 and r=-0.36, p=0.015, respectively) and with deceleration time (DT-ms) 
(r=-0.32, p=0.035 and r=-0.43, p=0.010, respectively). Serum levels of all the other molecules 
studied were similar in CHF and controls. 
Conclusions: Fibrosis suppressors such as BMPs are poorly expressed in the serum of CHF patients 
concomitantly to an increased serum level of the BMPs inhibitor CRIM1, which in turn, is tightly 
correlated with the serum PIP III increase, suggesting a progressive imbalance in favor of pro-
fibrotic mechanisms in CHF of increasing severity. 
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Introduction 
 
Increased collagen synthesis and degradation has been found in heart failure (1,2) and 
myocardial fibrosis is associated to development of Heart Failure (3,4). A number of 
studies performed in postmortem human hearts (5-7) and endomyocardial human 
biopsies have shown that fibrillar collagen deposition is increased in the myocardium of 
patients with left ventricular hypertrophy (8-12). Furthermore, fibrosis is higher in more 
advanced stages of HF and is associated with a poor prognosis (13-17). Serum 
concentrations of procollagen types (PIP) I and III can be considered as a useful 
markers of collagens type I and III synthesis (18). Serum collagens I and III 
concentrations can represent their turnover levels (18). A number of molecules may 
influence collagen turnover in HF of increasing severity. 
TGFβ1 and its receptors R1 and R2 are involved in downregulation of inflammation 
(19,20), can regulate vascular morphogenesis and extracellular matrix synthesis (21). A 
pro-angiogenic growth activity and increased cell survival stimulation has been reported 
for Stromal cell-derived factor-1α (SDF-1α) and its receptor CXCR4 (22,23). 
Fibroblasts growth factors (FGF)1 and 2 (acidic and basic, respectively) are involved in 
the regulation of cardiac angiogenesis and repair (24) and FGF2 is required for 
development of cardiac hypertrophy (25). Fibulins are involved in structural support, 
matrix-cell interactions and elastogenic activity (26). Circulating Bone Morphogenic 
Proteins (BMP) 1-3 may have a pro-fibrotic effect in the kidneys (27). BMP2 can 
suppresses renal interstitial fibrosis and TGFβ1 induced cardiac fibrosis (28,29). BMP4 
reduced TGFβ1 induced extracellular matrix tenascin C and fibronectin production in 
cultured lung fibroblasts (30). BMP4 inhibitor gremlin is over-expressed in idiopathic 
pulmonary fibrosis (31). BMP7 suppresses hepatic fibrosis (32), limits Smad3 DNA 
binding and decreases renal fibrosis (33), reduces collagen content in asbestos treated 
mice (31), preserves the endothelial cardiac phenotype avoiding the fibroblasts 
formation and fibrosis (34). BMP endothelial cell precursor derived regulator (BMPER) 
interacts with BMPs and when overexpressed antagonizes their function (35) or 
regulates BMPs function (36). Cysteine-rich motor neuron 1 (CRIM1) interacts with 
BMPs acting as an antagonist reducing production and processing of mature BMPs and 
decreasing secretion of BMPs (37,38). The BMP and activin membrane-bound inhibitor 
(BAMBI) is a membrane-spanning glycoprotein that acts as a negative regulator of 
TGFβ signaling (39). A prevalent anti-fibrotic activity was postulated for the pseudo-
receptor BAMBI that results up-regulated by TGFβ1 stimulation in the endothelium 
(40).  
Aim of the present study is to investigate serum/plasma biomarkers concentrations of 
fibrosis activators, fibrosis suppressors and regulators in patients with CHF of 
increasing severity and in a healthy control group of subjects and to evaluate possible 
correlations between fibrosis regulators and heart functional indexes. 
 
Methods 
Subjects 
The total study population comprised 80 subjects. The CHF group was composed of 66 
subjects with left ventricular dysfunction classified as follows: 9 in NYHA I, 34 in 
NYHA II and 23 in NYHA III. Characteristics of patients such as mean age, left 
ventricular ejection fraction (LVEF), sex, 6’WT, VO2max and etiology (ischemic (IHD) 
or idiopathic (ICM)) are summarized in tables 1 and 2. Table 2 shows a comparative 
analysis for age, LVEF%, 6’WT and VO2max between the IHD and ICM subgroups. 
Patients receiving intravenous infusions, with severe valvular disease or with significant 
renal insufficiency were excluded from the study. The control group included 14 
healthy volunteers matched for age and sex, without any documented history, signs or 
symptoms of heart failure, nor history of left ventricular dysfunction (table 1). Clinical 
information, including demographics, co-morbidities, medications, and symptom level 
based on NYHA classification, were collected in the week before blood sample 
collection. At enrolment, all subjects underwent complete echocardiographic study. Left 
ventricular volumes were calculated from orthogonal apical views using the biplane 
area-length method, and ejection fraction was derived from the standard equation. 
Deceleration time (DT) of early filling (ms) was measured, as a strong predictor of 
pulmonary capillary wedge pressure in patients with left ventricular dysfunction (41), 
irrespective of the degree of mitral regurgitation (42) or atrial fibrillation (43). 
The study was carried out in conformity with the Declaration of Helsinki, and informed 
consent was obtained from each subject. This cross-sectional study was performed 
according to the local Ethics Committee Guidelines. 
 
Serum collection and analysis 
Blood samples were collected using Bekton Dikinson (BD) Vacutainer Cat Plus REF 
367896 for serum. Serum or plasma was then aliquoted and immediately frozen at –80 
°C until analysis. The serum/plasma levels of all molecules (see table 3) were 
determined by commercially available enzyme linked immunosorbent assay (ELISA) 
kits as described in table 3. Table 3 also shows the lower detection limits and the 
method of quantification (ELISA) for each of the molecules studied. Manufacturers’ 
instructions were carefully followed for each of the ELISA kits used. Further details for 
each kit are available from the respective online datasheet. 
 
 
Data analysis 
Group data were expressed as mean  standard error for functional data or median 
(range or IQR) for serum/plasma levels data. Differences between groups were analysed 
using analysis of variance (ANOVA) for functional data. The Kruskal Wallis test was 
applied for serum/plasma levels data, followed - when differences were significant – by 
the Mann-Whitney U test for comparison between groups. Single regression analysis 
was performed using the Spearman correlation test. Probability values of p<0.05 were 
considered as significant. Data analysis was performed using the Stat View SE Graphics 
program (Abacus Concepts Inc., Berkeley, CA-USA).  
 
Results 
Subjects 
Characteristics of the study population are summarized in Table 1. Patients in NYHA 
class II and III were slightly older than NYHA I patients. Ischemic patients were 
slightly older (p=0.03) compared to idiopatic subjects and showed a significantly lower 
VO2max (p=0.01) (see table 2 for characteristics of patients when divided into ischemic 
and idiopathic subgroups). 
 
Quantification of serum/plasma markers  
Quantification of fibroblasts growth factor (FGF) basic and acidic and of Transforming 
Growth Factor (TGF)β1 were not statistically different in the four groups of subjects 
studied, showing a low presence of these molecules both in patients and control subjects 
(table 4). TGFβR1 was slightly decreased in NYHA class II (p=0.036) and III (p=0.020) 
compared to controls, even-though this difference was not revealed by Kruskal Wallis 
test for multiple comparisons. Interestingly, TGFβR2 increased significantly in NYHA 
class III compared to NYHA class II (p=0.011) and controls (p=0.018) (figure 1a). The 
TGFβ pseudo-receptor BAMBI was similarly expressed in all groups, showing a low 
expression in the four groups examined. The pro-angiogenic factor SDF1α was 
significantly increased in NYHA class III compared to NYHA class II (p=0.013), 
NYHA class I (p=0.014) and controls (p=0.0006) (figure 1b), at variance with its 
receptor CXCR4, which was similarly expressed in the four groups. Fibulins 1 and 2 
were highly expressed in all subjects without any significant differences between 
groups. Fibulin 4 was significantly higher in NYHA class III patients compared to 
NYHA I (p=0.011), even though this difference was not confirmed by the more 
restrictive statistical analysis for multiple comparisons, the Kruskal Wallis test. Among 
the BMPs (BMP1, BMP2, BMP3, BMP7, BMP10) proteins analysed, BMP1 and BMP2 
were the most abundantly expressed in all subjects without significant differences 
between groups. The BMP endothelial cell precursor derived regulator, BMPER is as 
well, modestly expressed, at a concentrations similar to BMP2, in all subjects without 
significant differences between groups. Interestingly, the BMPs antagonist CRIM1, was 
significantly higher in NYHA class III patients compared to NYHA class II (p=0.024), 
NYHA class I (p=0.011) and controls (p=0.054) (figure 1c). Collagen I and PIP I were 
similarly expressed in the four groups of patients studied. Collagen III was significantly 
higher in NYHA class III patients compared to controls (p=0.043). Most importantly, 
Procollagen (PIP) type III was significantly higher in NYHA class III patients compared 
to NYHA class II (p=0.0078), NYHA class I (p=0.047) and controls (p=0.0011) (figure 
1d). NYHA class II patients also differed significantly from controls (p=0.038). These 
results are summarized in table 4. 
 
When ischemic (IHD) were compared to idiopathic (ICM) patients, we did not observe 
any significant difference for all the molecules studied except for CRIM1 and Fibulin 4 
serum concentrations which were reported as significantly higher in IHD compared to 
ICM patients. These results are summarized in table 5. 
 
Correlations 
In our patient cohort, none of the biomarkers studied correlated significantly with 
LVEF% at echocardiography. PIP III was inversely correlated with 6’WT (r=-0.37, 
p=0.0086) (figure 2a) and DT (ms) (r=-0.32, p=0.035) (figure 2c). CRIM1 was 
inversely correlated with 6’WT (r=-0.36, p=0.0158) (figure 2b), peak VO2 (r=-0.53, 
p=0.0015) and DT (ms) (r=-0.43, p=0.010) (figure 2d). TGFβR2 was inversely 
correlated with DT (ms) (r=-0.35, p=0.027); SDF1α correlated inversely with peak VO2 
(r=-0.42, p=0.032). No other correlations were found between serum/plasma biomarkers 
and physiological/functional parameters. Interestingly, Pro-collagen type III (PIP III) 
was positively correlated with TGFβR2 (r=0.29, p=0.026) (figure 3a), CRIM1 (r=0.38, 
p=0.005) (figure 3b), Fibulin 4 (r=0.35, p=0.010) (figure 3c) and SDF1α (r=0.44, 
p=0.013) (figure 3d). 
 
 
Discussion  
In our CHF patients, we demonstrated increasing levels of Procollagen type III (PIP III), 
Transforming growth factor (TGF)βR2,  Stromal cell-derived factor(SDF)-1α and 
Cysteine-rich motor neuron (CRIM)-1, particularly in patients with more severe disease. 
PIP III serum levels correlated inversely with patient’s tolerance to dynamic exercise 
(6’WT) and to the ventilatory response (DTms). PIP III serum levels were also 
positively correlated with CRIM-1, SDF-1α, Fibulin-4 and TGFβR2 in the serum of 
CHF patients of increasing severity. These data, taken together, show a progressive 
imbalance in favour of pro fibrotic mechanisms, which can be revealed in the 
serum/plasma, in patients with CHF of increasing severity. 
The role of BMPs proteins as anti-fibrotic agents is sufficiently well documented in 
kidney (44) and liver (32). Relatively few data are disposable in heart fibrosis. Recently, 
it was showed that in mice, pressure overload induced collagen deposition was 
decreased and cardiac function improved, after 2 weeks treatment with recombinant 
BMP-2 (29), suggesting a fibrosis antagonizing action for this molecule. In the serum of 
our CHF patients BMP-1,-2, -3, -7 and -10 were poorly represented being BMP-1 and 
BMP-2 the most expressed BMPs proteins. None of the BMPs proteins showed 
significant changes in CHF patients compared to controls, suggesting that their potential 
role as anti-fibrotic molecules could not be exerted in CHF patients of increasing 
severity. Since a number of molecules, such as BMP endothelial cell precursor derived 
regulator (BMPER) and cysteine-rich motor neuron 1 (CRIM-1)  may have a regulatory 
or inhibitory role on BMPs proteins, we quantified these molecules in the serum of our 
CHF patients and controls. The BMPER serum levels were relatively low and similar in 
the four groups of patients studied, suggesting a minor role for this regulatory molecule. 
Interestingly, we found significantly increased serum levels of CRIM-1 in NYHA class 
III CHF patients when compared to all the other groups studied and CRIM-1 serum 
levels were positively correlated with PIP III serum levels in CHF patients (figure 3). A 
negative significant correlation was also observed between CRIM-1 serum levels and 
6’WT or DT(ms), showing, as an original contribution of the present study, a possible 
relationship between CRIM-1 levels and increased heart fibrosis, associated to a 
decreased ventilatory response and dynamic exercise performance of the patients (figure 
2). In “in vitro” experiments, CRIM-1 binding of BMP4 and -7 leads to a reduction in 
the production and secretion of mature BMPs (37) on metanephric explant cultures. 
These data, together with our “in vivo” findings of an increased serum level of CRIM-1, 
associated to low serum levels of BMPs, invite to speculate on the possible BMPs 
inhibitory role of CRIM-1 and subsequent increased heart fibrosis, in our patients with 
CHF of increasing severity. Interestingly, in the sub-group of CHF patients with 
ischaemic hearth disease (IHD), CRIM-1 and also Fibulin-4, a molecule involved in the 
elastic fiber assembly, are significantly increased as compared to idiopathic 
cardiomyopathy (ICM) group. Also PIP III levels tended to be higher (p=0.11) in IHD 
compared to ICM patients (see table 5), suggesting again a pro-fibrotic role for these 
proteins in the more compromised patients with CHF. 
The TGFβ pseudo-receptor BAMBI, for which a prevalent anti-fibrotic activity was 
reported (39,45), was similarly expressed in the four groups of subjects studied, 
suggesting a minor role for this protein in controlling the fibrotic changes developing in 
CHF of increasing severity. 
A pro-angiogenic growth activity has been reported for SDF1α and its receptor CXCR4 
(22,23). SDF1α was reported as increased in acute myocardial infarction (AMI) (22), 
suggesting a contribution of bone  marrow cells in myocardial regeneration (22). In 
CHF patients, a three months physical training significantly increased serum levels of 
the pro-angiogenic markers angiopoietin-2 and  CD34+ cells, but not of SDF1α, as 
compared with non-trained patients (46). In contrast, a down-regulation of pro-
angiogenic mechanisms, included SDF1α reduction, was reported in idiopathic 
pulmonary fibrosis (47), suggesting that potentially differing mechanisms could be 
involved in cardiac and lung fibrosis. We here reported a significantly increased serum 
level of SDF1α in NYHA class III patients compared to all the other groups of subjects 
and a significant positive correlation between SDF1α and PIP III serum levels in 
patients with CHF of increasing severity (figures 1 and 3), suggesting a role for this pro-
angiogenic molecule in heart remodelling. Since a parallel increase of its receptor 
CXCR4 was not observed in the plasma of our patients, the effective SDF1α biological 
activity developing in these patients needs to be more extensively elucidated by 
specifically designed “in vitro” studies.  
Fibulins have a role in the assembly and stabilization of supramolecular extracellular 
matrix (ECM) complexes. They also can function as a modulators of cell growth, 
differentiation and angiogenesis (48). Fibulin-1 and -2 interact with a wide number of 
ECM complexes, fibulin-4 interacts mainly with tropoelastin (48). Fibulins-1 and -2 
were the most expressed fibulins in the serum of our patients without significant 
differences between groups (table 4). Fibulin-4 was slightly increased in NYHA class 
III compared to NYHA class I  patients, and it was correlated positively with PIP III 
serum levels (figure 3), probably as a consequence of the more direct relationship of this 
fibulin type with the cardiac function (48). 
Molecules classically considered as fibrosis inductors, such as basic and acidic 
fibroblast growth factors and transforming growth factor(TGF)β1 were poorly 
recovered in the serum of our patients and controls (table 4), showing no significant 
differences between groups. TGFβRI was slightly decreased in NYHA class II and III 
CHF patients, compared to controls. Interestingly, TGFβRII serum levels, increased 
significantly in NYHA class III compared to NYHA class II patients and controls (table 
4) and correlated significantly with PIP III serum levels (figure 3), showing  a potential 
role in inducing heart remodelling and fibrosis. Pro-collagen (PIP) type I and collagen 
type I were similarly recovered in the serum of the four groups studied. As expected, 
PIP III serum level was significantly increased in NYHA class III compared to all the 
other groups and in NYHA class II compared to controls (table 4). Serum level of 
Collagen III was also slightly increased in NYHA class III compared to controls (table 
4), confirming the increased fibrotic state and collagen turnover in patients with CHF of 
increasing severity.  
The prognostic value of the CRIM-1 serum test, as well as inhibition of the CRIM-1 
biological functions and up-regulation of anti-fibrotic BMPs molecules need further 
specifically planned “in vitro” and “in vivo” studies.   
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Figure Legends 
 
 
Figure 1 
Transforming growth factor-β receptor 2 (TGF-βR2) (a), Stromal cell-derived factor-1α (SDF1α) 
(b), Cysteine-rich motor neuron-1 (CRIM1) (c) Pro-collagen type III (PIP III) (d), in serum/plasma 
of subjects with chronic heart failure from NYHA class I, II, III and healthy controls. The results 
are expressed as median (interquartile (IQR) range). Statistical analysis: Kruskal Wallis followed 
by Mann Whitney U test for comparison between groups. Control subjects: n=14; CHF NYHA  
class I: n=9; CHF NYHA class II: n=34; CHF NYHA class III: n=23. 
 
Figure 2 
  Regression analysis between PIP III and CRIM1 serum levels and six minutes walking test 
(6’WT) (a and b, respectively) and deceleration time (DT-ms) (c and d, respectively) in all patients 
with CHF (n=66). Spearman’s rank correlations. 
 
 
Figure 3 
Regression analysis between PIP III serum levels and pro-fibrotic stimuli TGFβR2 (a), CRIM1 (b), 
Fibulin 4 (c) and PIP III versus a pro-angiogenic stimulator SDF1α (d) in all patients with CHF 
(n=66). Spearman’s rank correlations. 
  
Tables 
 
Table 1 
Characteristics of CHF patients and healthy controls 
Subjects (n) Age 6WT' LVEF% VO2max Sex (M/F) IHD/ICM 
Controls (14) 53 ± 2  -  60±2  - 14/0  - 
NYHA I (9) 55 ± 4 486 ± 23 25 ± 2 20.8 ± 2.3 8/0  4/5 
NYHA II (34) 63 ± 2* 405 ± 14 27 ± 1 16 ± 1 31/3  22/12 
NYHA III (23) 65 ± 2* 276 ± 31 23 ± 1^ 13 ± 1  16/7  13/10 
  
Data expressed as Mean  SE; IHD = Ischemic Heart Disease; ICM = Idiopathic Cardiomyopathy;  
LVEF=Left ventricular ejection fraction; 6WT’=six minutes walking test; VO2max = maximal 
oxygen consumption. 
ANOVA: *p<0.05 from NYHA I; ^p<0.05 from NYHA II. 
 
 
 
Table 2 
 
Characteristics of ischemic and idiopathic CHF patients used for analysis of serum/plasma  
biomarkers 
 
Subjects (n) Age LVEF% 6’WT VO2max 
IHD (39) 652 261 40118 151 
ICM (27) 553* 241 43928 202** 
Data expressed as meanSE; IHD=Ischemic Heart Disease; ICM=Idiopathic Cardiomyopathy; 
LVEF =Left ventricular ejection fraction; 6WT = Six minutes walking text; VO2max = maximal 
oxygen consumption. 
ANOVA: *p=0.03; **p=0.010 
 
  
Table 3 
 Summary of the ELISA assays performed in the serum/plasma for biomarkers included in 
the study 
Molecules Manifacturer            
(code) 
Lower detection 
limit 
Type of 
plasma/serum 
Analytical Method 
FGF basic  R&D Systems          
DFB50 
3 pg/ml Serum ELISA  
FGF acidic  R&D Systems       
DFA00B 
5,68 pg/ml Serum ELISA  
TGF-β1  R&D Systems       
DB100B 
4,61 pg/ml Plasma ELISA  
TGF-β R1  USC  Life Science 
Inc.  E90397Hu 
0,118 ng/ml Serum ELISA  
TGF- β R2  USC Life Science 
Inc.  E92972Hu 
0,126 ng/ml Serum ELISA  
BAMBI  USC Life Science 
Inc.  E98566Hu 
0,064 ng/ml Serum ELISA  
SDF-1α  R&D Systems  
DSA00 
18 pg/ml Plasma ELISA  
CXCR4 CUSABIO 
CSB-E12825h 
3.9 pg/ml Plasma ELISA 
Fibulin 1  USC Life Science 
Inc.  E92472Hu 
0,23 ng/ml Serum ELISA  
Fibulin 2  USC Life Science 
Inc.  E93152Hu 
5,6 pg/ml Serum ELISA  
Fibulin 4  USC  Life Science 
Inc.  E95421Hu 
1,12 ng/ml Serum ELISA  
BMP-1  USC Life Science 
Inc.  E90653Hu 
0,064 ng/ml Serum ELISA  
BMP-2 USC Life Science 
Inc.  E90013Hu 
15,98 pg/ml Serum ELISA  
BMP-3  USC Life Science 
Inc.  E92102Hu 
27 pg/ml Serum ELISA  
BMP-7  USC Life Science 
Inc.  E90799Hu 
5,9 pg/ml Serum ELISA  
BMP-10  USC Life Science 
Inc.  E92106Hu 
0,066 ng/ml Serum ELISA  
BMPER  USC Life Science 
Inc.  E98548Hu 
0,059 ng/ml Serum ELISA  
CRIM-1  USC Life Science 
Inc.  E98548Hu 
0,13 ng/ml Serum ELISA  
PIP-I  TaKaRa                     
MK101 
10 ng/ml Serum ELISA  
PIP-III  USC Life Science 
Inc.  E90573Hu 
12,8 pg/ml Serum ELISA  
Collagen I  USC Life Science 
Inc.  E90571Hu 
0,237 ng/ml Serum ELISA  
Collagen III  USC Life Science 
Inc.  E90176Hu 
13,1 pg/ml Serum ELISA  
 
 
 
Table 4 
Quantification of pro-fibrotic molecules and growth factors in the serum/plasma of patients 
with chronic heart failure and control subjects 
 
Controls  NHYA I NHYA II    NHYA III       Kruskal-Wallis 
                      P- value 
 
FGF basic (pg/ml)  0(0-0.33)      0 (0-1.67)    0(0-9.07)          0(0-4.02)  0.4240 
FGF acidic (pg/ml)  0(0-38.07)  0(0-14.78)    0(0-468.41)       0(0-22.52)   0.2608 
TGF-β1 (ng/ml)  0(0-25.41)  0(0-8.6)    0(0-16.98)       0(0-18.18)  0.9657  
TGF-β R1 (ng/ml)  1.04(0.36-5.76) 0.84(0.01-20.84)   0.6(0-5.96)        0.44(0-4.2)      0.0724 
TGF- β R2 (ng/mL)  1.00(0-26.99)            2.37(1.13-23.61)    1.49(0-26.162)       4.29(0.476-32.784)  0.0176 
BAMBI (ng/mL)  0.24(0.18-1.11) 0.26(0.11-10.09) 0.22(0.07-1.24)    0.29(0.03-0.81)  0.3363 
SDF-1α (pg/mL)                  1853(1440-2179)       2035 (1743-3123)       2035 (1447-3604)          3088 (1736-4004)  0.0017 
CXCR4 (pg/ml)                          59(13-109)                     19(14-103)                  46(7-213)                        47(1-163)                             0.6997 
Fibulin 1 (ng/ml)       36700(16400-110500)    37650(17400-99400)   35000(16400-139200)    25700(14400-108500)   0.3272 
Fibulin 2 (ng/ml)                 615(141-2442)                 180(123-2189)             881(105-2664)              1165(126-2455)                   0.9345 
Fibulin 4 (ng/mL)                14.04(2.27-30.66)        7.52(2.50-14.27)          11.22(0.68-203.40)      16.27(5.91-60.60)   0.0651 
BMP-1 (ng/mL)  0.94(0.56-10.95) 1.50(0.80-10.40)   1.52(0.57-16.87)       2.03(0.84-9.45)    0.2645 
BMP-2 (pg/mL)          424(206-820)                   457(146-4760) 500(25-2328)                 288(109-1376)                   0.8584  
BMP-3 (pg/mL)  0(0-6782)                    0(0-4981)                     0(0-5331)          0(0-5043)    0.7661 
BMP-7 (pg/mL)  0(0-503)                   0(0-429)                    0(0-530)                         0(0-105)   0.8054 
BMP-10 (ng/ml)                0.02(0-1.8)                   0(0-8.8)     0(0-1.47)        0(0-1.8)    0.4457 
BMPER (ng/ml)                    0.50(0.39-2.93)            0.47(0.26-13.7)  0.46(0.22-2.02)      0.50(0.22-3.95)       0.5758    
CRIM-1 (ng/mL)                 1.18(0-5.23) 0.75(0-1.79)   1.16(0-26.10)       2.67(0-26.50)   0.0332 
PIP-I (ng/mL)           574(335-1417)               566(209-936)                 450(198-1310)      556(267-1421)   0.2589 
PIP-III (ng/mL)             48(20-87)                       50(29-159)                     67(28-147)                  106(25-262)                    0.0021 
Collagen I (ng/ml)           330(169-1000)               278(75-1000)                 292(76-1000)                  337(89-1000)    0.6347 
Collagen III (ng/ml)         5198(0-15062)               8083(172-22428)            5458(0-30840)               9400(0-64386)     0.2169 
 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------  
Result expressed as median (range) 
Mann-Whitney U test:  significantly different from controls p<0.05;  significantly different 
from NHYA I p<0.05;  significantly different from NHYA II p<0.05. 
 
 
 
 
 
 
 
 
 
 
  
Table 5. Median values of biomarkers in the serum/plasma of chronic heart failure patients 
according to ischaemic or idiopathic aetiology of the disease 
Subjects (n) CRIM 1  
(ng/mL) 
Fibulin 4 
 (ng/mL) 
PIP III 
(ng/mL) 
Collagen III  
(ng/mL) 
IHD (39) 
ICM (27) 
p-value 
2.2 (0-26.49) 
0.74 (0-2.17) 
0.0102 
15 (1.3-60) 
8.1 (0.68-16.62) 
0.0106 
83356 (26566-246472) 
53302 (27600-172952) 
0.115 
8168 (172-64386) 
8261 (0-31950) 
0.463 
Values are expressed as median (range). ICM, idiopathic cardiomyopathy; IHD, ischaemic 
hearth disease; CRIM1, Cysteine-rich motor neuron-1; PIP III, Pro-collagen type III. Mann-
Whitney U-test for comparison between groups. 
 
 
 
 
 
Tabella formattata
